Daiwa Securities Group Inc. Boosts Stock Position in Abbott Laboratories $ABT

Daiwa Securities Group Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 2.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 295,075 shares of the healthcare product maker’s stock after buying an additional 8,435 shares during the period. Daiwa Securities Group Inc.’s holdings in Abbott Laboratories were worth $36,970,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $27,000. Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $33,000. Leonteq Securities AG purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $35,000. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. Stifel Nicolaus lowered their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Barclays cut their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. BTIG Research reiterated a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a research note on Monday, April 27th. Wells Fargo & Company cut their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Bank of America cut their target price on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Price Performance

NYSE ABT opened at $90.71 on Friday. The business’s fifty day moving average price is $93.07 and its 200-day moving average price is $109.44. The stock has a market capitalization of $157.99 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 1.45 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.